|
|
 |
|
Viewing report
|
|
|
|
ADHD & Insomnia Treatments
ChangeWave, May 2006, Pages: 14
During the week of April 7-10, 2006 we surveyed ChangeWave Alliance healthcare industry members about ADHD and Insomnia treatments. A total of 102 members participated, including 36 clinicians directly involved with ADHD, and 69 respondents involved with Insomnia.
Questions Answered in this Report:
- Which drugs/treatments have been prescribed or recommended for ADHD patients under 18 years old? Over the age of 18?
- Have recent discussions about side effects and “black box” warnings for ADHD drugs made Physicians less likely to prescribe or recommend these drugs ?
- Has there been a reduction in patient acceptance of ADHD drugs as a result of recent discussions about side effects and “black box” warnings ?
- Which ADHD drugs will be most affected by recent discussions about side effects and “black box” warnings ?
- During the next 12 months, what is the likelihood physicians will prescribe or recommend Daytrana, the ADHD patch from Shire Pharmaceuticals, for children with ADHD?
- Which Insomnia drugs/treatments will be prescribed or recommended to patients 65 or older ? Under age 65?
- Has there been a reduction in patient acceptance of Insomnia drugs as a result of recent reports about side effects?
Reasons to purchase this report:
- Discover the most-prescribed ADHD treatments
- Learn the outlook for Adderall over the next 12 months
- Understand patient concerns over ADHD drugs
- Gain insight into the latest concerns about Insomnia Drugs
Customers who bought this item also bought
Commercial And Pipeline Insight: ADHD - Immature Adult Market Continues To Offer Greatest Commercial Potential
The ADD and ADHD Cure: The Natural Way to Treat Hyperactivity and Refocus Your Child
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
Pipeline Insight: Insomnia - Targeting The Sleep Maintenance Market
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
The ADD/ADHD Checklist: A Practical Reference for Parents and Teachers, 2nd Edition
Adult ADHD - Strattera Grows Up
U.S. Insomnia Therapies Markets
Pipeline and Commercial Perspectives: Insomnia
Commercial Insight: Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
Commercial Insight: ADHD - Strattera Reigns Supreme as Branded Stimulants Slump
Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
|
|
|
|
